Home › Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023
 

Keywords :   


Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023

2016-01-25 13:46:50| Biotech - Topix.net

Novavax, Inc. , a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 . The Notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Tags: due notes million senior

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06PPG to Announce Second-quarter 2024 Results July 18
26.06Fresh Coat for First Responders: New Hampshire Fire Station Gets a Makeover by California Paints
26.06Michigan Sets Record Recycling Rate in 2023, Recycles Nearly 70,000 Tons of Materials
26.06Companies Seek Federal EPR: How Producers Can Prepare
26.06Q&A with GFLs Tyler Stefure: Integrating New Fleet Tech & Upholding GFL Values
26.06SWANA Publishes Report on the Performance of Seattles Zero Waste System
26.06Baltimore Sues Major Brands for Alleged Role in Plastic Pollution Crisis
26.06Petco Aims Sight at Large-Scale Recycling Program to Divert LDPE Plastic from Landfills
More »